Component

C. zeylanicum escalating-dose water extract in the 2017 phase I study

C. zeylanicum escalating-dose water extract in the 2017 phase I study. Species, exposure and limitations are retained in each linked claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Blood pressure decreased during the uncontrolled phase I study, beginning in the first month.

    C. zeylanicum escalating-dose water extract in the 2017 phase I study → Arterial blood pressure source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/ceylon-research/29282046.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9f042ba36cfd9e3e8a8e76e155c71d6b742c431c1ba4cf90c3a94115f3b06c61", "start_char": 0, "end_char": 2508, "text_sha256": "9f042ba36cfd9e3e8a8e76e155c71d6b742c431c1ba4cf90c3a94115f3b06c61"}
    experimental_model
    Uncontrolled phase I escalating-dose study
    exposure
    30 enrolled, 28 completed; water extract 85, 250 and 500 mg at successive monthly intervals
    limitations
    No placebo group; three months and a small healthy sample cannot establish long-term safety or efficacy in disease.
    nutrient_topic
    Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. · Ceylon cinnamon / Cinnamomum verum bark preparations
    organism
    Human
    plain_language
    Blood pressure fell, but the study cannot separate extract effects from other changes over time.
    primary_references
    [ceylon-p29282046] Evaluation of pharmacodynamic properties and safety of Cinnamomum zeylanicum (Ceylon cinnamon) in healthy adults: a phase I clinical trial. (2017). https://pubmed.ncbi.nlm.nih.gov/29282046/ DOI: 10.1186/s12906-017-2067-7
    tissue_or_cell_type
    Healthy adults, clinical and laboratory measures

    Ceylon cinnamon: metabolism, signaling and nutrient connections (2026-09-17) · lines 1130–1141

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Uncontrolled phase I escalating-dose study · source_derived_draft · unverified_draft

    ### ceylon-phase1-bp Blood pressure decreased during the uncontrolled phase I study, beginning in the first month. Condition category: normal nutrient_topic: Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. plain_language: Blood pressure fell, but the study cannot separate extract effects from other changes over time. organism: Human tissue_or_cell_type: Healthy adults, clinical and laboratory measures experimental_model: Uncontrolled phase I escalating-dose study limitations: No placebo group; three months and a small healthy sample cannot establish long-term safety or efficacy in disease. exposure: 30 enrolled, 28 completed; water extract 85, 250 and 500 mg at successive monthly intervals evidence_span: {"source_cache": "artifacts/ceylon-research/29282046.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9f042ba36cfd9e3e8a8e76e155c71d6b742c431c1ba4cf90c3a94115f3b06c61", "start_char": 0, "end_char": 2508, "text_sha256": "9f042ba36cfd9e3e8a8e76e155c71d6b742c431c1ba4cf90c3a94115f3b06c61"} [ceylon-p29282046] Evaluation of pharmacodynamic properties and safety of Cinnamomum zeylanicum (Ceylon cinnamon) in healthy adults: a phase I clinical trial. (2017). https://pubmed.ncbi.nlm.nih.gov/29282046/ DOI: 10.1186/s12906-017-2067-7
    Complete structured claim and evidence

  2. Two of 30 enrolled participants discontinued the phase I study because of dyspepsia.

    C. zeylanicum escalating-dose water extract in the 2017 phase I study → Dyspepsia-associated withdrawal in the Ceylon phase I study source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/ceylon-research/29282046.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9f042ba36cfd9e3e8a8e76e155c71d6b742c431c1ba4cf90c3a94115f3b06c61", "start_char": 0, "end_char": 2508, "text_sha256": "9f042ba36cfd9e3e8a8e76e155c71d6b742c431c1ba4cf90c3a94115f3b06c61"}
    experimental_model
    Uncontrolled phase I escalating-dose study
    exposure
    30 enrolled, 28 completed; water extract 85, 250 and 500 mg at successive monthly intervals
    limitations
    No placebo group; three months and a small healthy sample cannot establish long-term safety or efficacy in disease.
    nutrient_topic
    Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. · Ceylon cinnamon / Cinnamomum verum bark preparations
    organism
    Human
    plain_language
    Stomach discomfort was important enough for two people to stop.
    primary_references
    [ceylon-p29282046] Evaluation of pharmacodynamic properties and safety of Cinnamomum zeylanicum (Ceylon cinnamon) in healthy adults: a phase I clinical trial. (2017). https://pubmed.ncbi.nlm.nih.gov/29282046/ DOI: 10.1186/s12906-017-2067-7
    tissue_or_cell_type
    Healthy adults, clinical and laboratory measures

    Ceylon cinnamon: metabolism, signaling and nutrient connections (2026-09-17) · lines 1117–1128

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Uncontrolled phase I escalating-dose study · source_derived_draft · unverified_draft

    ### ceylon-phase1-dyspepsia Two of 30 enrolled participants discontinued the phase I study because of dyspepsia. Condition category: normal nutrient_topic: Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. plain_language: Stomach discomfort was important enough for two people to stop. organism: Human tissue_or_cell_type: Healthy adults, clinical and laboratory measures experimental_model: Uncontrolled phase I escalating-dose study limitations: No placebo group; three months and a small healthy sample cannot establish long-term safety or efficacy in disease. exposure: 30 enrolled, 28 completed; water extract 85, 250 and 500 mg at successive monthly intervals evidence_span: {"source_cache": "artifacts/ceylon-research/29282046.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9f042ba36cfd9e3e8a8e76e155c71d6b742c431c1ba4cf90c3a94115f3b06c61", "start_char": 0, "end_char": 2508, "text_sha256": "9f042ba36cfd9e3e8a8e76e155c71d6b742c431c1ba4cf90c3a94115f3b06c61"} [ceylon-p29282046] Evaluation of pharmacodynamic properties and safety of Cinnamomum zeylanicum (Ceylon cinnamon) in healthy adults: a phase I clinical trial. (2017). https://pubmed.ncbi.nlm.nih.gov/29282046/ DOI: 10.1186/s12906-017-2067-7
    Complete structured claim and evidence

  3. Liver tests remained within the normal range without significant alteration during the three-month phase I study.

    C. zeylanicum escalating-dose water extract in the 2017 phase I study → Liver test results during the Ceylon phase I study source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/ceylon-research/29282046.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9f042ba36cfd9e3e8a8e76e155c71d6b742c431c1ba4cf90c3a94115f3b06c61", "start_char": 0, "end_char": 2508, "text_sha256": "9f042ba36cfd9e3e8a8e76e155c71d6b742c431c1ba4cf90c3a94115f3b06c61"}
    experimental_model
    Uncontrolled phase I escalating-dose study
    exposure
    30 enrolled, 28 completed; water extract 85, 250 and 500 mg at successive monthly intervals
    limitations
    No placebo group; three months and a small healthy sample cannot establish long-term safety or efficacy in disease.
    nutrient_topic
    Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. · Ceylon cinnamon / Cinnamomum verum bark preparations
    organism
    Human
    plain_language
    The small study found no laboratory liver signal during its observation period.
    primary_references
    [ceylon-p29282046] Evaluation of pharmacodynamic properties and safety of Cinnamomum zeylanicum (Ceylon cinnamon) in healthy adults: a phase I clinical trial. (2017). https://pubmed.ncbi.nlm.nih.gov/29282046/ DOI: 10.1186/s12906-017-2067-7
    tissue_or_cell_type
    Healthy adults, clinical and laboratory measures

    Ceylon cinnamon: metabolism, signaling and nutrient connections (2026-09-17) · lines 1104–1115

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Uncontrolled phase I escalating-dose study · source_derived_draft · unverified_draft

    ### ceylon-phase1-liver Liver tests remained within the normal range without significant alteration during the three-month phase I study. Condition category: normal nutrient_topic: Ceylon cinnamon research collection; topical membership is not evidence of a direct dietary effect. plain_language: The small study found no laboratory liver signal during its observation period. organism: Human tissue_or_cell_type: Healthy adults, clinical and laboratory measures experimental_model: Uncontrolled phase I escalating-dose study limitations: No placebo group; three months and a small healthy sample cannot establish long-term safety or efficacy in disease. exposure: 30 enrolled, 28 completed; water extract 85, 250 and 500 mg at successive monthly intervals evidence_span: {"source_cache": "artifacts/ceylon-research/29282046.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "9f042ba36cfd9e3e8a8e76e155c71d6b742c431c1ba4cf90c3a94115f3b06c61", "start_char": 0, "end_char": 2508, "text_sha256": "9f042ba36cfd9e3e8a8e76e155c71d6b742c431c1ba4cf90c3a94115f3b06c61"} [ceylon-p29282046] Evaluation of pharmacodynamic properties and safety of Cinnamomum zeylanicum (Ceylon cinnamon) in healthy adults: a phase I clinical trial. (2017). https://pubmed.ncbi.nlm.nih.gov/29282046/ DOI: 10.1186/s12906-017-2067-7
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards